
Paula Peyrani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1896458/publications.pdf

Version: 2024-02-01



Δλιιίλ Δενδληί

#	Article	IF	CITATIONS
1	Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine, 2022, 40, 1872-1878.	3.8	2
2	Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review. Infectious Diseases and Therapy, 2022, 11, 937-951.	4.0	10
3	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	5.8	33
4	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine, 2021, 39, 5428-5435.	3.8	36
5	Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 1272-1279.	3.3	3
6	A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases, 2020, 20, 426.	2.9	6
7	3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents. Open Forum Infectious Diseases, 2020, 7, S23-S24.	0.9	1
8	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine, 2019, 37, 3352-3361.	3.8	54